Since the start of the coronavirus disease 2019 (COVID-19) pandemic, several biomarkers have been proposed to assess the diagnosis and prognosis of this disease. The present systematic review evaluated endocan (a marker of endothelial cell damage) as a potential diagnostic and prognostic biomarker for COVID-19. PubMed, Scopus, Web of Science, and Embase were searched for studies comparing circulating endocan levels between COVID-19 cases and controls, and/or different severities/complications of COVID-19. Eight studies (686 individuals) were included, from which four reported significantly higher levels of endocan in COVID-19 cases compared with healthy controls. More severe disease was also associated with higher endocan levels in some of the studies. Studies reported higher endocan levels in patients who died from COVID-19, were admitted to an intensive care unit, and had COVID-19-related complications. Endocan also acted as a diagnostic and prognostic biomarker with different cut-offs. In conclusion, endocan could be a novel diagnostic and prognostic biomarker for COVID-19. Further studies with larger sample sizes are warranted to evaluate this role of endocan.
YukiKFujiogiMKoutsogiannakiS. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427.
2.
KanjiJNZelyasNMacDonaldC, et al.False negative rate of COVID-19 PCR testing: a discordant testing analysis. Virol J. 2021;18:13.
3.
KaliAShettyKS. Endocan: a novel circulating proteoglycan. Indian J Pharmacol. 2014;46:579-583.
4.
YücelMKotanDGurol ÇiftçiGÇiftçiIHCikriklarHI. Serum levels of endocan, claudin-5 and cytokines in migraine. Eur Rev Med Pharmacol Sci. 2016;20:930-936.
5.
BaltaSMikhailidisDPDemirkolSOzturkCCelikTEndocanIA. A novel inflammatory indicator in cardiovascular disease?Atherosclerosis. 2015;243:339-343.
6.
KechagiaMPapassotiriouIGourgoulianisKI. Endocan and the respiratory system: a review. Int J Chronic Obstr Pulm Dis. 2016;11:3179-3187.
7.
QianYLeiTPatelPS, et al.Direct activation of endothelial cells by sars-cov-2 nucleocapsid protein is blocked by simvastatin. J Virol. 2021;95:e0139621.
8.
XuS-WIlyasIWengJ-P. Endothelial dysfunction in COVID-19: an overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2022:1-15.
9.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
10.
WellsGSheaBO’ConnellD, et al.The newcastle–ottawa Scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000.
11.
Chenevier-GobeauxCDucastelMMeritetJF, et al.Plasma endocan as a biomarker of thrombotic events in COVID-19 patients. J Clin Med. 2022;11:5560.
12.
GaudetAGhozlanBDupontA, et al.Derivation and validation of a predictive score for respiratory failure worsening leading to secondary intubation in COVID-19: the ceres score. J Clin Med. 2022;11:2172.
13.
GorgunSCindorukSOzgenE, et al.Diagnostic and prognostic value of serum endocan levels in patients with COVID-19. Angiology. 2021;72:942-946.
14.
GuzelDKalkanEAErenF, et al.Can serum endocan levels be used as an early prognostic marker for endothelial dysfunction in COVID-19?Angiology. 2022;73:438-444.
15.
KimWYKweonOJChaMJBaekMSChoiSH. Dexamethasone may improve severe COVID-19 via ameliorating endothelial injury and inflammation: a preliminary pilot study. PLoS One. 2021;16:e0254167.
16.
LalogluEAlayH. Endocan as a potential marker in diagnosis and predicting disease severity in COVID-19 patients: a promising biomarker for patients with false-negative RT-PCR. Ups J Med Sci. 2022;127:e8211.
17.
MedetalibeyogluAEmetSKoseM, et al.Serum endocan levels on admission are associated with worse clinical outcomes in COVID-19 patients: a pilot study. Angiology. 2021;72:187-193.
18.
PascreauTTcherakianCZuberBFarfourEVasseMLassalleP. A high blood endocan profile during COVID-19 distinguishes moderate from severe acute respiratory distress syndrome. Crit Care. 2021;25:166.
19.
FodorATiperciucBLoginC, et al.Endothelial dysfunction, inflammation, and oxidative stress in COVID-19-mechanisms and therapeutic targets. Oxid Med Cell Longev. 2021;2021:8671713-8671715.
20.
GuSXTyagiTJainK, et al.Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation. Nat Rev Cardiol. 2021;18:194-209.
21.
AckermannMVerledenSEKuehnelM, et al.Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383:120-128.
22.
du PreezHNAldousCHaydenMRKrugerHGLinJ. Pathogenesis of COVID-19 described through the lens of an undersulfated and degraded epithelial and endothelial glycocalyx. Faseb J. 2022;36:e22052.
23.
MartinLKoczeraPZechendorfESchuerholzT. The endothelial glycocalyx: new diagnostic and therapeutic approaches in sepsis. BioMed Res Int. 2016;2016:3758278.
24.
SarrazinSLyonMDeakinJA, et al.Characterization and binding activity of the chondroitin/dermatan sulfate chain from endocan, a soluble endothelial proteoglycan. Glycobiology. 2010;20:1380-1388.
25.
ZhangSMZuoLZhouQ, et al.Expression and distribution of endocan in human tissues. Biotech Histochem. 2012;87:172-178.
26.
AfsarBTakirMKostekOCovicAKanbayM. Endocan: a new molecule playing a role in the development of hypertension and chronic kidney disease?J Clin Hypertens. 2014;16:914-916.
27.
LeiteARBorges-CanhaMCardosoRNevesJSCastro-FerreiraRLeite-MoreiraA. Novel biomarkers for evaluation of endothelial dysfunction. Angiology. 2020;71:397-410.
28.
ZhaoTKechengYZhaoX, et al.The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: a meta-analysis. Medicine (Baltim). 2018;97:e13407.
29.
ChenJJiangLYuXH, et al.Endocan: a key player of cardiovascular disease. Front Cardiovasc Med. 2021;8:798699.
30.
KlisicAKavaricNVujcicSSpasojevic-KalimanovskaVNinicAKotur-StevuljevicJ, et al.Endocan and advanced oxidation protein products in adult population with hypertension. Eur Rev Med Pharmacol Sci. 2020;24:7131-7137.
31.
ZiaeeMMashayekhiSGhaffariSMahmoudiJSarbakhshPGarjaniA. Predictive value of endocan based on timi risk score on major adverse cardiovascular events after acute coronary syndrome. Angiology. 2019;70:952-959.
32.
IcliACureECureMC, et al.Endocan levels and subclinical atherosclerosis in patients with systemic lupus erythematosus. Angiology. 2016;67:749-755.
33.
NalbantoğluAKızılcaÖGüzelSEmeksizHCNalbantoğluB. Increased carotid intima-media thickness and endothelial cell-specific molecule-1 (endocan) levels in obese children. Angiology. 2021;72:633-639.
34.
ArmanYAkpinarTSKoseM, et al.Effect of glycemic regulation on endocan levels in patients with diabetes: a preliminary study. Angiology. 2016;67:239-244.
35.
MetschlSBruderLPaloschiV, et al.Changes in endocan and dermatan sulfate are associated with biomechanical properties of abdominal aortic wall during aneurysm expansion and rupture. Thromb Haemost. 2022;122:1513-1523.
36.
LongBBradyWJKoyfmanAGottliebM. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38:1504-1507.
37.
RamandiAAkbarzadehMAKhaheshiIKhalilianMR. Aortic dissection and Covid-19; a comprehensive systematic review. Curr Probl Cardiol. 2022:101129.
38.
HanFLiaoWDuanXShiYHuZ. The association between serum endocan level and short-term prognosis of patients with acute ischemic stroke. Angiology. 2022;73:344-349.
39.
LaloğluFLaloğluECevizNGülerMA. Serum endocan levels in children with rheumatic aortic insufficiency: can it differentiate bicuspid aortic valve disease from rheumatic heart disease?Cardiol Young. 2022:1-5.
40.
YilmazMISiriopolDSaglamM, et al.Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney Int. 2014;86:1213-1220.
41.
LandstraCPde Koning EJP. COVID-19 and diabetes: understanding the interrelationship and risks for a severe course. Front Endocrinol. 2021;12:649525.
42.
SheppardJPNicholsonBDLeeJ, et al.Association between blood pressure control and coronavirus disease 2019 outcomes in 45 418 symptomatic patients with hypertension: an observational cohort study. Hypertension. 2021;77:846-855.
43.
JarromDElstonLWashingtonJ, et al.Effectiveness of tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19 diagnosis: a rapid systematic review. BMJ Evidence-Based Medicine. 2022;27:33-45.
44.
SeoKKitazawaTYoshinoYKogaIOtaY. Characteristics of serum endocan levels in infection. PLoS One. 2015;10:e0123358.
45.
LuoDWanXLiuJTongT. Optimally estimating the sample mean from the sample size, median, mid-range and/or mid-quartile range. Stat Methods Med Res. 2018;27:1785-1805.
46.
WanXWangWLiuJTongT. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
